Recommendations for preventive vaccination against Covid-19 in patients with lung cancer
Keywords:
Lung cancer, Covid-19, SARS-CoV-2, Vaccination, RecommendationsAbstract
Introduction: Patients with lung neoplasms are especially susceptible to suffering severe forms of Covid-19 and dying from complications derived from it. Vaccines against SARS-CoV-2 prevent infection and the development of severe conditions. For the immunization of cancer patients, the characteristics of the neoplasia and of the oncospecific treatments must be taken into account.
Objective: Describe recommendations for vaccination against Covid-19 in patients with lung cancer.
Methodological Design: A review of bibliographic articles in specialized sources was carried out. Twenty-seven documents relevant to the investigation were analyzed and useful information was extracted to prepare the report.
Development: Vaccines are safe and effective for the immunization of patients with lung cancer, except those that contain live or attenuated viruses. The oncospecific treatment regimen is not modified, it is recommended to administer the vaccine before starting treatment. Those who undergo surgery will receive the vaccine with a difference of seven days between the intervention and the injection, urgent surgeries will not be delayed regardless of the vaccination status of the individual. If they are immunosuppressed, they will have to be evaluated in a multidisciplinary way to establish the best time for vaccination. Lung transplant recipients will be vaccinated one month after the operation.
Conclusions: Specific measures should be taken into account for immunization against Covid-19 in patients with lung cancer according to the characteristics of the lesion and its treatment.
Downloads
References
2. European Society for Medical Oncology. Thoracic Tumours: Essentials for Clinicians. Oncology.Pro [Internet]. 2019 [citado 05/02/2022]. Disponible en: https://oncologypro.esmo.org/education-library/essentials-for-clinicians/thoracic-tumours/chapter-1-epidemiology-pathogenesis-and-risk-factors
3. Ministerio de Salud Pública de Cuba. Anuario Estadístico de Salud 2020 [Internet]. La Habana: MINSAP; 2021 [citado 05/02/2022]. Disponible en: https://temas.sld.cu/estadisticassalud/2021/08/11/anuario-estadistico-de-salud-2020/
4. Oficina Nacional de Estadística e Información. Anuario Estadístico de Cuba 2020. Salud Pública y Asistencia Social [Internet]. La Habana: ONEI; 2021 [citado 05/02/2022]. Disponible en: http://www.onei.gob.cu/sites/default/files/19_salud_2020.pdf
5. Camacho Sosa K, Ramírez Rodríguez D, Alonso Triana L, La Rosa Iznaga D. Revisión bibliográfica sobre la COVID 19 en pacientes con cáncer de pulmón. Rev Méd Electrón [Internet]. 2021 [citado 05/02/2022];43(1):220-31. Disponible en: http://www.revmedicaelectronica.sld.cu/index.php/rme/article/view/3921
6. Covid-19 Crisis del coronavirus. Datosmacro [Internet]. 2022 [citado 05/02/2022]. Disponible en: https://datosmacro.expansion.com/otros/coronavirus
7. MINSAP. Coronavirus en Cuba, 30 de enero de 2022 [Internet]. CECMED. 2022 [citado 05/02/2022]. Disponible en: https://www.cecmed.cu/noticias/coronavirus-cuba-30-enero-2022
8. Lara Álvarez MA, Rogado Revuelta J, Obispo Portero B, Pangua Méndez C, Serrano Montero G, López Alfonso A. Mortalidad por COVID-19 en pacientes con cáncer en un hospital de Madrid durante las primeras 3 semanas de epidemia. Medicina Clínica [Internet]. 2020 [citado 05/02/2022];155(5):202-4. Disponible en: https://www.elsevier.es/es-revista-medicina-clinica-2-articulo-mortalidad-por-covid-19-pacientes-con-S0025775320302815
9. Villar Álvarez F, Martínez García MÁ, Jiménez D, Fariñas Guerrero F, Ortiz de Lejarazu LR, López Campos JL, et al. Recomendaciones SEPAR sobre la vacuna COVID-19 en las enfermedades respiratorias. Open Respiratory Archives [Internet]. 2021 [citado 05/02/2022]; 3(2):100-15. Disponible en: https://www.elsevier.es/en-revista-open-respiratory-archives-11-articulo-recomendaciones-separ-sobre-vacuna-covid-19-S2659663621000163
10. MINSAP. Actualización de la estrategia para el desarrollo de las vacunas cubanas [Internet]. Sitio oficial de gobierno del Ministerio de Salud Pública de Cuba. 2021 [citado 05/02/2022]. Disponible en: https://salud.msp.gob.cu/actualizacion-de-la-vacunacion-en-el-marco-de-los-estudios-de-los-candidatos-vacunales-cubanos-y-la-intervencion-sanitaria/
11. Castañeda CA, Castillo M, Rojas JL, Fuentes H, Gómez HL. COVID-19 en pacientes con cáncer: revisión sistemática. Rev Peru Med Exp Salud Publica [Internet]. 2020 [citado 05/02/2022];37(4):611-9. Disponible en: https://doi.org/10.17843/rpmesp.2020.374.5976
12. Rogado J, Serrano Montero G, Pangua C. Características y evolución de los pacientes con cáncer de pulmón e infección Covid-19 en un hospital de segundo nivel durante los 3 primeros meses de pandemia. Med Clin (Barc) [Internet]. 2020 [citado 05/02/2022]; 155(9):411–3. Disponible en: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7381900/
13. Ruiz Galiana J, Cantón R, De Lucas Ramos P, García Botella A, García Lledó A, Gómez-Pavón J, et al. COVID-19 vaccination: the reality after clinical trials. Rev Esp Quimioter [Internet]. 2021 [citado 05/02/2022];34(5):408–18. Disponible en: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8638833/
14. Grupo Español de Cáncer de Pulmón. Estudio SOLID archivos. GECP [Internet]. 2022 [citado 05/02/2022]. Disponible en: https://www.gecp.org/tag/estudio-solid/
15. Sánchez Ríos CP, Ramírez Candelas MA, Menchaca Dávila SA, Martínez Barrera LM, Rodríguez Cid JR, Alatorre Alexander JA. COVID-19: recomendaciones generales y especificaciones para el paciente con cáncer de pulmón avanzado. Revisión de la literatura. Neumología y Cirugía de Tórax [Internet]. 2020 [citado 05/02/2022]; 79(2):101-9. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=94636
16. Picazo JJ. Vaccine against COVID-19. Rev Esp Quimioter [Internet]. 2021 [citado 05/02/2022];34(6):559–98. Disponible en: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8638770/
17. del Rio Mendoza J, Becerra Canales BD, Miranda Soberon U. Aceptabilidad de la vacuna contra la covid-19, en adultos de una región del Perú. Revista Médica Panacea [Internet]. 2022 [citado 05/02/2022];10(3):99–104. Disponible en: https://revistas.unica.edu.pe/index.php/panacea/article/view/446
18. Gounant V, Ferré VM, Soussi G, Charpentier C, Flament H, Fidouh N, et al. Efficacy of severe acute respiratory syndrome Coronavirus-2 vaccine in patients with thoracic cancer: A prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses. J Thorac Oncol [Internet]. 2022 [citado 05/02/2022];17(2):239–51. Disponible en: https://www.jto.org/article/S1556-0864(21)03286-X/fulltext
19. European Society for Medical Oncology. ESMO Statements on vaccination against COVID-19 in people with cancer. ESMO [Internet]. 2021 [citado 05/02/2022]. Disponible en: https://www.esmo.org/covid-19-and-cancer/covid-19-vaccination
20. American Association for Cancer Research. Cancer researchers working to combat the COVID-19 pandemic. AACR [Internet]. 2022 [citado 05/02/2022]. Disponible en: https://www.aacr.org/professionals/research/aacr-covid-19-and-cancer-report-2022/cancer-researchers-working-to-combat-the-covid-19-pandemic/
21. American Society of Clinical Oncology. COVID-19 vaccines & patients with cancer. ASCO [Internet]. 2021 [citado 05/02/2022]. Disponible en: https://www.asco.org/covid-resources/vaccines-patients-cancer
22. Soto Pérez de Celis E, Arrieta O, Bargalló Rocha E, Campos Gómez S, Chávarri Guerra Y, Chávez Nogueda J, et al. Recomendaciones de la Sociedad Mexicana de Oncología para la vacunación contra Covid-19 en personas con cáncer en México. Salud Publica Mex [Internet]. 2022 [citado 05/02/2022];64(1):114-5. Disponible en: https://saludpublica.mx/index.php/spm/article/view/12745
23. Acosta Castro FE, Vinces Sornoza TP, Triviño Lopez SB. Eficacia y efectos secundarios de la vacuna contra el COVID 19. Dominio las Cienc [Internet]. 2021 [citado 05/02/2022];7(2):1079–87. Disponible en: https://dominiodelasciencias.com/ojs/index.php/es/article/view/1847/html
24. Pineda Palacios WG, Rivas Astudillo JA, Saraguro León GA, Solano Espinoza JA, Valdivieso Tocto NK, Álvarez Álvarez DP. Vacuna Johnson & Johnson contra COVID-19: distribución mundial de la vacuna, mecanismo de acción, indicaciones, contraindicaciones y efectos secundarios. Una revisión bibliográfica. Rev ADM [Internet]. 2021 [citado 05/02/2022];78(5):275-9. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=102035
25. Suárez Rodríguez C, Collado Falcón JC. Características y tratamiento del paciente oncológico en el marco de la actual pandemia de la COVID-19. Rev haban cienc méd [Internet]. 2020 [citado 05/02/2022]; 19(Suppl 1): e3396. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2020000400007&lng=es
26. Federación de Asociaciones Científico Médicas Españolas. Recomendaciones FACME para la vacunación frente a COVID-19. FACME [Internet]. 2021 [citado 05/02/2022]. Disponible en: https://seom.org/images/FACME_tests_diagnosticos.pdf
27. Gómez Rincón JC. Situación actual de la pandemia y el paciente con cáncer. Rev colomb cancerol [Internet]. 2021 [citado 05/02/2022];25(2):61–4. Disponible en: https://www.revistacancercol.org/index.php/cancer/article/view/810
Downloads
Published
How to Cite
Issue
Section
License
Those authors who have publications with this journal accept the following terms: The authors will retain their copyright and guarantee the journal the right of first publication of their work, which will be simultaneously subject to the Recognition License. Creative Commons that allows third parties to share the work as long as its author and its first publication in this magazine are indicated. Authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a monographic volume) as long as the initial publication in this journal is indicated. Authors are allowed and recommended to disseminate their work through the Internet (e.g.: in institutional telematic archives or on your website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work.
